Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prithviraj Bose

Showing results (41-50 of 224) with videos related to

Pageof 23
Sort By:
Expert Opinion on Investigational Drugs|November 28, 2024
Investigational drugs in early phase trials for myelofibrosisSankalp Arora, Pankit Vachhani, Prithviraj Bose
Oncotarget|February 27, 2013
Coordinate PI3K pathway and Bcl-2 family disruption in AMLPrithviraj Bose, Mohamed Rahmani, Steven Grant
Leukemia & Lymphoma|February 1, 2017
Pathways and mechanisms of venetoclax resistancePrithviraj Bose, Varsha Gandhi, Marina Konopleva
Clinical Lymphoma, Myeloma & Leukemia|February 10, 2024
SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic MyelofibrosisPankit Vachhani, Sanam Loghavi, Prithviraj Bose
Current Treatment Options in Oncology|January 25, 2019
New Concepts of Treatment for Patients with MyelofibrosisPrithviraj Bose, Mansour Alfayez, Srdan Verstovsek
Current Hematologic Malignancy Reports|June 23, 2019
The Rationale for Immunotherapy in Myeloproliferative NeoplasmsLucia Masarova, Prithviraj Bose, Srdan Verstovsek
Expert Opinion on Pharmacotherapy|April 18, 2023
Cytopenic myelofibrosis: prevalence, relevance, and treatmentPankit Vachhani, Srdan Verstovsek, Prithviraj Bose
Expert Opinion on Investigational Drugs|July 23, 2020
Givinostat: an emerging treatment for polycythemia veraHelen T Chifotides, Prithviraj Bose, Srdan Verstovsek
Journal of Hematology & Oncology|January 20, 2022
Momelotinib: an emerging treatment for myelofibrosis patients with anemiaHelen T Chifotides, Prithviraj Bose, Srdan Verstovsek
Cancers|July 14, 2023
Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and TreatmentsHelen T Chifotides, Srdan Verstovsek, Prithviraj Bose
Pageof 23

Showing results (41-50 of 224) with videos related to

Sort By:
Pageof 23
Expert Opinion on Investigational Drugs|November 28, 2024
Investigational drugs in early phase trials for myelofibrosisSankalp Arora, Pankit Vachhani, Prithviraj Bose
Oncotarget|February 27, 2013
Coordinate PI3K pathway and Bcl-2 family disruption in AMLPrithviraj Bose, Mohamed Rahmani, Steven Grant
Leukemia & Lymphoma|February 1, 2017
Pathways and mechanisms of venetoclax resistancePrithviraj Bose, Varsha Gandhi, Marina Konopleva
Clinical Lymphoma, Myeloma & Leukemia|February 10, 2024
SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic MyelofibrosisPankit Vachhani, Sanam Loghavi, Prithviraj Bose
Current Treatment Options in Oncology|January 25, 2019
New Concepts of Treatment for Patients with MyelofibrosisPrithviraj Bose, Mansour Alfayez, Srdan Verstovsek
Current Hematologic Malignancy Reports|June 23, 2019
The Rationale for Immunotherapy in Myeloproliferative NeoplasmsLucia Masarova, Prithviraj Bose, Srdan Verstovsek
Expert Opinion on Pharmacotherapy|April 18, 2023
Cytopenic myelofibrosis: prevalence, relevance, and treatmentPankit Vachhani, Srdan Verstovsek, Prithviraj Bose
Expert Opinion on Investigational Drugs|July 23, 2020
Givinostat: an emerging treatment for polycythemia veraHelen T Chifotides, Prithviraj Bose, Srdan Verstovsek
Journal of Hematology & Oncology|January 20, 2022
Momelotinib: an emerging treatment for myelofibrosis patients with anemiaHelen T Chifotides, Prithviraj Bose, Srdan Verstovsek
Cancers|July 14, 2023
Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and TreatmentsHelen T Chifotides, Srdan Verstovsek, Prithviraj Bose
Pageof 23